A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation

Abstract Aims To determine whether changing patterns of anticoagulant use in atrial fibrillation (AF) have impacted on stroke rates in England. Methods and results English national databases, 2006–2016, were interrogated to assess stroke admissions and oral anticoagulant use. The number of patients with known AF increased linearly from 692 054 to 983 254 (prevalence 1.29% vs. 1.71%). Hospital episodes of AF-related stroke/100 000 AF patients increased from 80/week in 2006 to 98/week in 2011 and declined to 86/week in 2016 (2006–2011 difference 18.0, 95% confidence interval (CI) 17.9–18.1, 2011–2016 difference −12.0, 95% CI −12.1 to −11.9). Anticoagulant use amongst patients with CHA2DS2-VASc ≥2 increased from 48.0% to 78.6% and anti-platelet use declined from 42.9% to 16.1%; the greatest rate of change occurred in the second 5 year period (for anticoagulants 2006–2011 difference 4.8%, 95% CI 4.5–5.1%, 2011–2016 difference 25.8%, 95% CI 25.5–26.1%). After adjustment for AF prevalence, a 1% increase in anticoagulant use was associated with a 0.8% decrease in the weekly rate of AF-related stroke (incidence rate ratio 0.992, 95% CI 0.989–0.994). Had the use of anticoagulants remained at 2009 levels, 4068 (95% CI 4046–4089) more strokes would have been predicted in 2015/2016. Conclusion Between 2006 and 2016, AF prevalence and anticoagulant use in England increased. From 2011, hospitalized AF-related stroke rates declined and were significantly associated with increased anticoagulant uptake.

[1]  A. Hess,et al.  Management. , 2020, Anesthesiology.

[2]  Michael B. Gravenor,et al.  Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study , 2017, Circulation.

[3]  Mircea Cinteza,et al.  A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial , 2017, The Lancet.

[4]  V. Mok,et al.  Age-specific trends of atrial fibrillation-related ischaemic stroke and transient ischaemic attack, anticoagulant use and risk factor profile in Chinese population: a 15-year study , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  C. Sindet-Pedersen,et al.  Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark , 2017, European heart journal.

[6]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[7]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[10]  G. Lip,et al.  Stroke prevention in atrial fibrillation , 2016, The Lancet.

[11]  B. Gersh,et al.  No Decline in the Risk of Stroke Following Incident Atrial Fibrillation Since 2000 in the Community: A Concerning Trend , 2016, Journal of the American Heart Association.

[12]  T. Uejima,et al.  Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation - Shinken Database Analysis. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[13]  P. Rothwell,et al.  Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  C. Martinez,et al.  Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013 , 2015, Heart.

[15]  C. Martinez,et al.  Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC , 2015, Thrombosis and Haemostasis.

[16]  Sudha Seshadri,et al.  50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study , 2015, The Lancet.

[17]  G. Hankey,et al.  Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[18]  Mårten Rosenqvist,et al.  High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke , 2014, Stroke.

[19]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[20]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[21]  C. Gale,et al.  The use of anticoagulants in the management of atrial fibrillation among general practices in England , 2013, Heart.

[22]  C. Herzog,et al.  Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992-2007). , 2013, JAMA internal medicine.

[23]  T. Holt,et al.  Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. , 2012, The British journal of general practice : the journal of the Royal College of General Practitioners.

[24]  是恒 之宏,et al.  ガイドライン解説 The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC) : Guidelines for the management of atrial fibrillation , 2011 .

[25]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[26]  G. Lip,et al.  Underuse of oral anticoagulants in atrial fibrillation: a systematic review. , 2010, The American journal of medicine.

[27]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[28]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[29]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[30]  KjellAsplund,et al.  High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke , 2014 .

[31]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.